Lu, Jianqin
Assistant Professor
所属大学: The University of Arizona
所属学院: Health Sciences
个人主页:
https://www.pharmacy.arizona.edu/directory/profile/jianqin-lu-bpharm-phd
个人简介
Jianqin Lu, BPharm, PhD, Assistant Professor of Pharmaceutical Sciences in Pharmaceutics and Pharmacokinetics, Department of Pharmacology and Toxicology. The overarching goal of the Lu lab is to apply synthetic chemistry, nanoparticle engineering, and tumor immunology to develop efficacious nanotherapeutics to address the pressing unmet needs in current cancer therapy. The Lu Lab's expertise in Pharmaceutics, Drug Delivery, Nanomedicine and Tumor Immunology paves the way to develop transformative and clinically translatable nano-enabled immunotherapeutics for combatting cancers. Post-Doctoral, Nanomedicine/Tumor Immunology, University of California, Los Angeles 2019 Post-Doctoral, Nanomedicine, The University of Chicago, 2015 PhD, Pharmaceutics, University of Pittsburgh, 2014 BS, Pharmacy, Hunan University of Chinese Medicine (China), 2010
研究领域
Drug Delivery Nanomedicine Pharmaceutics and Pharmacokinetics Nano-ImmunoEngineering Cancer Immunotherapy and Chemotherapy Biomaterials
近期论文
Wang Z, Chen J, Little N, Lu J. "Self-assembling Prodrug Nanotherapeutics for Synergistic Tumor Targeted Drug Delivery." Acta Biomater. 2020. PMCID: PMC7245299 PMID: 32454086 Lu J, Liu X, Liao Y-P, et al. "Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression." Nat Commun. 2017;8(1):1811. PMCID: PMC5703845 PMID: 29180759 Lu J, Liu C, Wang P, et al. "The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin." Biomaterials. 2015;62:176-87. PMCID: PMC4470812 PMID: 26057133 Lu J, Zhao W, Liu H, et al. "An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance." J Control Release. 2014;196:272-86. PMCID: PMC4267990 PMID: 25456831 Lu J, Huang Y, Zhao W, et al. "PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers." Biomaterials. 2013;34(5):1591-600. PMCID: PMC3529003 PMID: 23182923